Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 8;58(1):94.
doi: 10.3390/medicina58010094.

Rheumatological Adverse Events Following Immunotherapy for Cancer

Ioana Cretu  1 , Bogdan Cretu  2 , Catalin Cirstoiu  2 , Adrian Cursaru  2 , Mihaela Milicescu  1 , Mihai Bojinca  1 , Ruxandra Ionescu  3
Affiliations

Rheumatological Adverse Events Following Immunotherapy for Cancer

Ioana Cretu et al. Medicina (Kaunas). .

Abstract

Background and Objectives: The occurrence of rheumatological side effects in a patient after receiving immunotherapy for cancer is becoming increasingly common. Oncologists often fail to diagnose and refer affected patients to rheumatologists. This paper presents the various rheumatological adverse events that occur after immunotherapy in patients as well as their treatment and evolution. Materials and Methods: A total of 36 patients were monitored between November 2018 and March 2020. The oncologist monitoring the immunotherapy-treated patients identified the occurrence of musculoskeletal side effects. The grading of toxicities was performed by both the oncologist and the rheumatologist using common terminology criteria for adverse events (CTCAE). Rheumatological treatment was administered, and for some patients, immunotherapy was discontinued. Results: The clinical presentations of the patients varied. Mild side effects (grade 1-2) were reported in a higher proportion than severe side effects (grade 3-5). Therefore, thirty-one patients had mild-to-moderate side effects, and five patients had severe side effects. Adverse reactions occurred, on average, 10 weeks after the initiation of immunotherapy; this indicated that the severity of the toxicity was dose dependent. Patients were treated with NSAIDs or prednisone, depending on the severity of the side effects, and for patients with severe manifestations, immunotherapy was discontinued. The remission of rheumatic manifestations varied depending on the grade of the manifestations. Conclusions: The clinical, biological, and ultrasound presentations of the patients with adverse events followed by cancer treatments differed from classic rheumatological manifestations. Thorough examinations of these patients by both oncologists and rheumatologists are needed in order to correctly diagnose and treat rheumatological adverse events. Multiple studies that include a larger number of participants are needed in order to better understand the pathogenesis and clinical evolution of these patients under different treatment conditions.

Keywords: immune checkpoint inhibitors; immune-related adverse events; immunotherapy; rheumatological adverse events.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient with arthritis and tenosynovitis.
See this image and copyright information in PMC

References

    1. Melissaropoulos K., Klavdianou K., Filippopoulou A., Kalofonou F., Kalofonos H., Daoussis D. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. Int. J. Mol. Sci. 2020;21:3389. doi: 10.3390/ijms21093389. - DOI - PMC - PubMed
    1. Sangro B., Chan S.L., Meyer T., Reig M., El-Khoueiry A., Galle P.R. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J. Hepatol. 2020;72:320–341. doi: 10.1016/j.jhep.2019.10.021. - DOI - PMC - PubMed
    1. Moura C.A. Checkpoint inhibitors and arthritis: Seeking balance between victories and defeats. Ann. Rheum. Dis. 2018;78:e91. doi: 10.1136/annrheumdis-2018-213866. - DOI - PubMed
    1. Weinmann S.C., Pisetsky D.S. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology. 2019;58:vii59–vii67. doi: 10.1093/rheumatology/kez308. - DOI - PMC - PubMed
    1. Jenkins R.W., Barbie D.A., Flaherty K.T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer. 2018;118:9–16. doi: 10.1038/bjc.2017.434. - DOI - PMC - PubMed

MeSH terms

Substances